Press "Enter" to skip to content

GSK’s Experimental HIV Injection Receives Boost from Study

GlaxoSmithKline’s HIV injection trial is as effective when given monthly, according to research, a convenience that would help the British drug manufacturer in its fight against a competing drug from Gilead Sciences. GSK’s two-drug injection was as useful as a month-to-month dose of the same regimen in sustaining viral suppression at 48 weeks in a last-stage study, said ViiV Healthcare, GSK’s HIV unit.

Specific outcomes will be provided at a general medical conference, the corporate added.

ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combos and will use the lower drug weight in comparison with three-drug cocktails similar to Gilead’s Biktarvy as its primary selling point to sufferers and physicians.

It’s banking on longer-time period studies to yield hard proof of fewer unwanted effects over time.

While its once-a-day tablet Dovato, further a two-drug combination, won U.S. market approval in April, the corporate is following up with an extended-appearing injection combining the two active substances cabotegravir and Janssen’s rilpivirine.

The injection has beforehand proven to be as efficient as usual daily tablets with three active substances when administered month-to-month. Thursday’s outcomes showed that doubling the time between doses doesn’t compromise efficacy or safety.

The trial focused on the HIV-1 class of the AIDS virus, which has probably the most popular strains. If not checked, an HIV infection causes AIDS, a lethal condition that severely impairs the immune system.

U.S. drug manufacturer Gilead rules the HIV market, and it’ll keep up the stress with fast-rising Biktarvy, which was accredited in early 2018. Analysts on average, expect sales from the product to reach $5 billion next year, based on Refinitiv data.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *